LON:AVO - Advanced Oncotherapy Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 48.50 -3.50 (-6.73 %) (As of 05/20/2019 12:54 PM ET)Previous CloseGBX 52Today's RangeGBX 47.10 - GBX 51.8052-Week RangeGBX 33 - GBX 60Volume264,096 shsAverage Volume79,755 shsMarket Capitalization£94.36 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Related Properties. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also rents a medical facility. It has operations in the United Kingdom, Switzerland, and the Unites States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy PLC was incorporated in 2005 and is headquartered in London, the United Kingdom. Receive AVO News and Ratings via Email Sign-up to receive the latest news and ratings for AVO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolLON:AVO Previous Symbol CUSIPN/A CIKN/A Webwww.advancedoncotherapy.com Phone+44-20-36178728Debt Debt-to-Equity RatioN/A Current Ratio4.99 Quick Ratio2.18Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 1.96 per share Price / Cash Flow24.76 Book ValueGBX 35.40 per share Price / Book1.37Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees93 Outstanding Shares194,566,000Market Cap£94.36 million Next Earnings Date6/26/2019 (Estimated) OptionableNot Optionable Advanced Oncotherapy (LON:AVO) Frequently Asked Questions What is Advanced Oncotherapy's stock symbol? Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO." When is Advanced Oncotherapy's next earnings date? Advanced Oncotherapy is scheduled to release their next quarterly earnings announcement on Wednesday, June 26th 2019. View Earnings Estimates for Advanced Oncotherapy. Has Advanced Oncotherapy been receiving favorable news coverage? News stories about AVO stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Advanced Oncotherapy earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Advanced Oncotherapy's key competitors? Some companies that are related to Advanced Oncotherapy include Creo Medical Group (CREO), Medica Group (MGP), Hamilton Thorne (HTL), Titan Medical (TMD), Cyclopharm (CYC), Impedimed (IPD), Helius Medical Technologies (HSM), Kromek Group (KMK), REVA Medical (RVA), Osprey Medical (OSP), Resonance Health (RHT), Protech Home Medical (PHM), Electromed (ELMD), Universal Biosensors (UBI) and Avacta Group (AVCT). What other stocks do shareholders of Advanced Oncotherapy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Avesoro Resources (ASO), BMR Group (BMR), Lancashire (LRE), Sirius Minerals (SXX), Oxford BioMedica (OXB), Renishaw (RSW), GW Pharmaceuticals PLC- (GWPH), Scancell (SCLP) and Rose Petroleum (ROSE). Who are Advanced Oncotherapy's key executives? Advanced Oncotherapy's management team includes the folowing people: Dr. Michael Jeffrey Sinclair, Exec. Chairman (Age 76)Mr. Nicolas Serandour, CEO & Exec. DirectorMr. Ed Lee, COO & Sr. VP of OperationsMr. Graham Pughe, Sr. Vice-Pres, Accounting & ITMs. Geraldine Poindron, Corp. Fin. Mang. How do I buy shares of Advanced Oncotherapy? Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Advanced Oncotherapy's stock price today? One share of AVO stock can currently be purchased for approximately GBX 48.50. How big of a company is Advanced Oncotherapy? Advanced Oncotherapy has a market capitalization of £94.36 million. Advanced Oncotherapy employs 93 workers across the globe. What is Advanced Oncotherapy's official website? The official website for Advanced Oncotherapy is http://www.advancedoncotherapy.com/. How can I contact Advanced Oncotherapy? Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728. MarketBeat Community Rating for Advanced Oncotherapy (LON AVO)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 173 (Vote Outperform)Underperform Votes: 227 (Vote Underperform)Total Votes: 400MarketBeat's community ratings are surveys of what our community members think about Advanced Oncotherapy and other stocks. Vote "Outperform" if you believe AVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Overbought Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.